Navigation Links
ViroPharma Announces Appointment of Frank Baldino, Jr., Ph.D. to Board of Directors
Date:6/8/2009

EXTON, Pa., June 8 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced the appointment of Frank Baldino, Jr., Ph.D. to its board of directors.

Dr. Baldino brings several decades of pharmaceutical and health care industry experience and leadership to ViroPharma. He is the chief executive officer and chairman of the board of directors of Cephalon Inc., an international biopharmaceutical company in Chester County, Pennsylvania. Dr. Baldino founded Cephalon in 1987 and has served as chief executive officer and director since its inception.

Prior to joining Cephalon, he served as senior research biologist in the medical products department at E.I. duPont de Nemours & Company, where he was responsible for developing research strategies for identifying novel neuropharmaceutical agents. He has authored more than 100 publications in peer-reviewed journals such as Nature, Journal of Neuroscience Research, and Brain Research. Dr. Baldino received his Ph.D. in pharmacology from Temple University.

Dr. Baldino previously served as a member of ViroPharma's board of directors from 1996 to 2006.

"We are extremely pleased to welcome Frank Baldino, one of the most successful biopharmaceutical entrepreneurs, back to our board of directors," commented Vincent Milano, president and chief executive officer of ViroPharma. "For over a decade, Frank was an extraordinarily valuable member of our board, and we benefited significantly from his guidance and his experience. He brings to ViroPharma a wealth of experience in virtually any issue that a growing pharmaceutical company might encounter, and we are thrilled to welcome him back to our board."

"I am excited to have the opportunity to serve again on the board of directors of ViroPharma; I am proud of the success that the company has achieved and look forward to helping guide the company to its next level of growth and achievement," commented Dr. Baldino.

Dr. Baldino chairs the Executive Council of the Harvard Division of Sleep Medicine and is a member of the Board of Trustees at Temple University and The Franklin (formerly known as The Franklin Institute). In addition, he serves as a member of the Board of Directors for the Greater Philadelphia Chamber of Commerce, the Eastern Technology Council, BioAdvance Biotechnology Greenhouse Corp., Quaker BioVentures, L.P., and Pennsylvania BIO. Dr. Baldino is also a member of the Board of Directors for NicOx, S.A., and Acusphere, Inc.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. ViroPharma commercializes Cinryze(TM) (C1 esterase inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ViroPharma Announces Meeting of FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology on Bioequivalence Recommendations for Oral Vancomycin Hydrochloride Products
2. ViroPharma to Present at Two May Healthcare Conferences
3. ViroPharma to Present at the Cowen & Company 29th Annual Healthcare Conference
4. ViroPharma to Host Investor Teach-In Educational Symposium on Hereditary Angioedema
5. ViroPharma to Release 2008 Fourth Quarter and Full Year Financial Results on February 24, 2009
6. ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
7. ViroPharma to Present at the 27th Annual J.P. Morgan Healthcare Conference
8. ViroPharma Provides Update on Vancocin(R)
9. ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema
10. ViroPharma To Present At The 20th Annual Piper Jaffray Healthcare Conference
11. ViroPharma to Discuss Commercialization and Launch of Cinryze(TM) on November 5, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... PARK RIDGE, Ill. and INDIANAPOLIS ... caliber of students receiving a Lilly Diabetes Tomorrow,s Leaders ... hands. The 2016 scholarship winners, announced today online at ... refused to let type 1 diabetes stand in the ... Lilly Diabetes has supported the Foundation,s scholarship program since ...
(Date:6/23/2016)... -- The vast majority of dialysis patients currently receive ... usually 3 times a week, with treatment times averaging ... equipment preparation and wait time.  This regimen can be ... who are elderly and frail.  Many elderly dialysis patients ... for some duration of time. Residents in ...
Breaking Medicine Technology: